Aug 23 (Reuters) - The U.S. FDA is ramping up its investigation of the clinical trials that tested an MDMA-based therapy, the Wall Street Journal reported on Friday, citing people familiar with the matter. nThe Food and Drug Administrati
Aug 15 (Reuters) - Lykos Therapeutics will lay off 75% of its workforce, or about 100 employees, and founder Rick Doblin will leave the board, the company said on Thursday, days after the U.S. FDA declined approval for its MDMA-based PTSD treatment.
Lykos Therapeutics Announces Reorganization to Address FDA's Recent Decision on Midomafetamine Capsules for PTSD
Psychopharmacology has pulled three articles about midstage clinical trial data assessing Lykos Therapeutics’ investigational MDMA candidate for treating post-traumatic stress disorder (PTSD). The journal cited “unethical conduct” at a research site as the reason for the retraction.
MAPS remains confident in its goal of making access to MDMA-assisted therapy for PTSD safe and legal SAN JOSE, Calif., Aug. 09, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for...
PharmAla expresses disappointment in USFDA's decision to request a third Phase 3 for MDMA and announces the patent granting for a safer MDMA analog variant
A key independent drug pricing organization has concluded that the available evidence for Lykos Therapeutics’ MDMA-assisted psychotherapy is “insufficient”
A week after an FDA committee declined to support an midomafetamine (MDMA) treatment for post-traumatic stress disorder (PTSD), Lykos Therapeutics is looking to dispel some concerns about the therapy as the discussion has taken on a life of its own beyond the biotech world.
Long dismissed by top scientists and drug regulators, the use of psychedelics to treat mental health conditions has finally gained momentum over the last several years. But some proponents believe that progress was undercut this week, when one of the field’s most advanced therapies hit a significant setback.
US FDA panel votes against first MDMA-based PTSD treatment